Nykode Bruised But Not Broken After Roche Split

The Norwegian biotech is losing a big pharma partner and up to half of its staff, but remains confident about the prospects for its personalized cancer vaccine programs.

CEO Michael Engsig and CSO/head of BD Agnete Fredriksen (Nykode)

Norway’s Nykode Therapeutics is coming to terms with Roche’s surprise decision earlier this month to end the firms' cancer vaccine partnership, with significant job losses an inevitable consequence.

The Oslo-headquartered group was stunned when Roche’s Genentech subsidiary said on 7 November that it would be pulling out of...

More from Deals

More from Therapy Areas

BMS/Pfizer To Sell Discounted Eliquis Direct – And Other Drugmakers May Follow Suit

 

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.